source
- Genmab’s Rina-S ADC shows 9.5-month median PFS, touted as superior to AbbVie’s ElahereGenmab reported median progression‑free survival of 9.5 months for its FRα‑directed antibody‑drug conjugate Rina‑S in part C of the phase 1/2 Rainfol‑01 trial, which enrolled 109 patients with plat…
- Nova Biomedical issues global correction for StatStrip Glucose Hospital Meter over software patient-ID errorNova Biomedical announced a global medical device correction for its StatStrip Glucose Hospital Meter System. The correction targets a software issue in the Gen 2.0 model that can leave prior pati…